IMUNON signs an NCI agreement to expand development of IMNN-001

IMUNON ($IMNN) entered a Cooperative Research and Development Agreement with the US National Cancer Institute for IMNN-001, its DNA-based IL-12 immunotherapy. NCI’s Cancer Therapy Evaluation Program will assume regulatory sponsorship and support clinical and nonclinical work exploring additional solid-tumor indications and treatment combinations. The collaboration extends beyond the company’s ongoing ovarian-cancer program.

IMUNON retains its background intellectual property and ownership of new intellectual property generated solely by the company, along with rights to use collaboration data for development of IMNN-001. Management said the arrangement would let it explore broader uses while concentrating its own team on the pivotal OVATION 3 study. The agreement supplies a research framework and access to NCI infrastructure; it does not constitute regulatory approval or report new evidence that the therapy works in the additional indications.

Sources:

• IMUNON — NCI cooperative research agreement